CONTROLLED SUBSTANCES AND CBD PRODUCTS

(Updated 05/25/2022)

I. CODE OF FEDERAL REGULATIONS: 14 CFR 67.107 and 67.113(b)(c); 67.207 and 67.213(b)(c); 67.307 and 67.313(b)(c)

II. MEDICAL HISTORY: Item 48 or 18. n.

III. AEROMEDICAL DECISION CONSIDERATIONS: See Item 48. General Systemic

IV. PROTOCOL: N/A

V. PHARMACEUTICAL CONSIDERATIONS

• DEA Schedule Controlled Substances have aeromedically concerning safety profiles.

Additional Information Required (Used as a single agent or in any combination product.)			
CBD (cannabidiol) or products containing CBD	 Marijuana contains CBD and THC. With the exception of Epidiolex, CBD oil and other CBD-containing products are neither FDA approved nor regulated. The safety, efficacy, purity, and potency have not been adequately demonstrated. 1. Use of CBD or CBD-containing products is not specifically disqualifying. 2. The condition for which the product is being used may be disqualifying. Review a current detailed Clinical Progress Note to verify the underlying condition. 3. A marijuana-positive DOT drug test resulting from CBD use (intentional or inadvertent) is treated as a POSITIVE test. 		

UNACCEPTABLE Medications (Used as a single agent or in any combination product.)			
DEA SCHEDULE I	ALL Medications in this class but not limited to:		
Controlled Substances	MDMA ("Ecstasy," "Molly") GHB (gamma-hydroxybutyric acid) Heroin (diacetylmorphine) Khat (Cathinone, Cathine) • Synthetic Cathinones ("bath salts" Marijuana (cannabis, THC) • Medical Marijuana • Synthetic marijuana ("Spice," "	,	
DEA	Not limited to:		
SCHEDULE II	Barbiturates		
Controlled	Cocaine		
Substances	Stimulants Narcotics*		

^{*}The AME must review ANY use of narcotics. No fly or no Safety Related Duties during use. A minimum no fly time must be observed after last use. Frequent flares/ episodes require review of the underlying condition.